Open access · US-GOV
via ClinicalTrials.gov Clinical trial
The Swedish BioFINDER - Preclinical AD Study
Authors not listed
Skane University Hospital · 2022
Abstract
This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Skåne University Hospital in Sweden. The study will enroll up to 600 cognitively healthy subjects aged 50 to 80 years with 3/4 having preclinical Alzheimer's disease. Recruitment and enrollment will be ongoing for 2-3 years, and subject participation will be lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2022). The Swedish BioFINDER - Preclinical AD Study. <em>Skane University Hospital</em>. https://clinicaltrials.gov/study/NCT06121544
Vancouver
Anonymous. The Swedish BioFINDER - Preclinical AD Study. Skane University Hospital. 2022.
BibTeX
@misc{anon2022TheSwe,
title = {The Swedish BioFINDER - Preclinical AD Study},
author = {Anonymous},
journal = {Skane University Hospital},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Annovis Bio Inc. 2020
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)
University of Colorado, Denver 2016
Open access · US-GOV
Appetite Regulation in Older-Aged Obese Individuals
Aleksandra Stark 2017
Open access · US-GOV
A Phase IIa Proof of Concept, Randomized, Double-blind, Placebo-controlled Study of the Effects of L-serine on Early Stage Alzheimer's Disease Patients
Sonexa Therapeutics, Inc. 2009
Open access · US-GOV
A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease
University of Vigo 2026
Open access · US-GOV
Observational Study of Frailty and Fall Risk in Older Adults Included in the Frailty and Falls Prevention Program at the Centro Integral de Saúde de Lalín
Wake Forest University Health Sciences 2023
Open access · US-GOV